- Neurotech International’s (NTI) preclinical research demonstrates its proprietary cannabis strain can improve Diclofenac efficacy at low doses
- When combined with Neurotech’s NTI164, Diclofenac showed a 93 per cent reduction in the expression of TNF-alpha, an 80 per cent reduction in the expression of IL-6, as well as an up to a 66 per cent reduction in other key biomarkers
- The company says given the impending release of its final autism spectrum disorder study results, the company is well positioned for a busy second half to the year
- Neurotech is now working to secure strategic partners and undertake further clinical trials
- Neurotech International dips 7.69 per cent, trading at six cents at market close
Neurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.
Neurotech’s cannabis strain, NTI164, contains high levels of unique minor cannabinoids and less than 0.3 per cent THC.
Preclinical studies conducted in human cells showed NTI164, when combined with Diclofenac – the pharmaceutical active found in Voltaren – significantly reduced and normalised the levels of key inflammatory biomarkers in human neuronal cells. Diclofenac alone had a significantly lesser effect on these markers.
These key biomarkers are associated with the onset and development of multiple neuroinflammatory disorders including multiple sclerosis and Alzheimer’s disease, as well as inflammatory auto-immune diseases such as rheumatoid arthritis.
When combined with NTI164, Diclofenac’s effect was enhanced and showed a 93 per cent reduction in the expression of TNF-alpha, an 80 per cent reduction in the expression of IL-6, as well as an up to a 66 per cent reduction in other key biomarkers.
Neurotech said reducing the Diclofenac dose could also overcome some of the unwanted adverse side effects that are currently related to the dosage of Diclofenac.
Chairman of Neurotech International Brian Leedman said these preclinical results are incredibly exciting.
“We now have both Prednisone and Diclofenac, two very commonly used off-patent pharmaceutical drugs for inflammatory disorders, demonstrating significant improvement in effect using up to 90 per cent less active dosage when used in combination with NTI164,” Mr Leedman said.
“The potential to create combination treatments with NTI164 plus Diclofenac and Prednisone that increases efficacy and significantly reduces side effects is now a major driver for the company.”
The company said given the impending release of its final autism spectrum disorder study results, the company is well and truly positioned for an extremely busy second half to the year.
Neurotech is now working to secure strategic partners and undertake further clinical trials.
Neurotech International dipped 7.69 per cent, trading at six cents at market close.